https://crstodayeurope.com/news/sightsavers-health-project-provides-hope-for-millions-to-avoid-a-national-eye-health-crisis/2483704/daily0.7https://crstodayeurope.com/news/sightglass-vision-highlights-new-myopia-control-spectacle-lens-technology/2481524/daily0.7https://crstodayeurope.com/news/yuyu-pharma-presents-two-scientific-abstracts-at-arvo-examining-novel-peptide-yp-p10-for-dry-eye-disease/2483703/daily0.7https://crstodayeurope.com/news/lumata-health-and-prevent-blindness-announce-partnership-aimed-at-delivering-more-resources-to-americans-with-vision-loss/2481522/daily0.7https://crstodayeurope.com/news/nidek-announces-the-winners-of-the-3rd-annual-images-of-the-year-award/2481521/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-names-new-regional-presidents/2483702/daily0.7https://crstodayeurope.com/news/researchers-explain-how-reading-might-contribute-to-myopia/2481520/daily0.7https://crstodayeurope.com/news/radius-announces-perimeter-software-upgrade-for-wearable-device/2481518/daily0.7https://crstodayeurope.com/news/eversight-launches-preloaded-dmek-endoglide-1/2481517/daily0.7https://crstodayeurope.com/news/horus-pharma-group-launches-nordic-subsidiary/2481515/daily0.7https://crstodayeurope.com/news/celanese-enters-agreement-with-glaukos-corporation-for-sustained-release-glaucoma-treatment/2481514/daily0.7https://crstodayeurope.com/news/centricy-study-finds-zepto-precision-pulse-capsulotomy-offers-advantages-over-manual-capsulorhexis-in-treating-white-cataracts/2481513/daily0.7https://crstodayeurope.com/news/first-myopia-action-month-announced-for-september/2481510/daily0.7https://crstodayeurope.com/news/sight-sciences-appoints-ali-bauerlein-as-chief-financial-officer/2481509/daily0.7https://crstodayeurope.com/news/tearrestores-thermal-mask-hylawipe-tea-tree-eyelid-wipes-now-available-at-target/2481508/daily0.7https://crstodayeurope.com/news/us-lowers-cut-to-medicare-advantage-payments/2483701/daily0.7https://crstodayeurope.com/news/astrazenecas-ultomiris-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-adults-with-nmosd/2483700/daily0.7https://crstodayeurope.com/news/wavefront-dynamics-launches-wavedyn-vision-analyzer/2481503/daily0.7https://crstodayeurope.com/news/fda-approves-twice-daily-dosing-of-vuity-for-adults-with-presbyopia/2481502/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-appoints-francis-mah-md-as-chief-medical-advisor/2481501/daily0.7https://crstodayeurope.com/news/andreas-c-kuhnel-appointed-as-geschaftsfuhrer-managing-director-at-vsy-biotechnology/2481500/daily0.7https://crstodayeurope.com/news/staar-surgical-names-warren-foust-chief-operating-officer-magda-michna-phd-chief-clinical-regulatory-and-medical-affairs-officer/2481498/daily0.7https://crstodayeurope.com/news/thea-open-innovation-and-galimedix-partner-to-develop-and-commercialize-gal-101-for-ophthalmic-indications/2481497/daily0.7https://crstodayeurope.com/news/survey-employees-value-vision-care-as-much-as-dental-but-many-are-leaving-benefits-on-the-table/2481495/daily0.7https://crstodayeurope.com/news/cellusion-announces-first-patient-transplanted-ipsc-derived-corneal-endothelial-cell-substitute-cls001/2481493/daily0.7https://crstodayeurope.com/news/international-sports-vision-association-announces-leadership-appointments-of-new-executive-and-advisory-board-officers/2481491/daily0.7https://crstodayeurope.com/news/oertli-instrumente-opens-oertli-ophtha-lab-at-the-lucerne-university-of-applied-sciences-and-arts-1/2481489/daily0.7https://crstodayeurope.com/news/cdc-cases-of-vision-loss-and-death-due-to-drug-resistant-bacteria-linked-to-artificial-tears-continues-to-rise/2481488/daily0.7https://crstodayeurope.com/news/haag-streit-launches-new-corneal-ectasia-display-for-the-eyestar-900/2481487/daily0.7https://crstodayeurope.com/news/aurion-biotech-receives-approval-in-japan-for-first-allogeneic-cell-therapy-to-treat-corneal-endothelial-disease/2481486/daily0.7https://crstodayeurope.com/news/bausch-lomb-and-novaliq-announce-publication-of-second-pivotal-phase-3-data-on-nov03-perfluorohexyloctane/2481485/daily0.7https://crstodayeurope.com/news/visus-therapeutics-completes-enrollment-in-brio-i-a-phase-3-clinical-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481483/daily0.7https://crstodayeurope.com/news/the-american-diabetes-association-and-genentech-partner-to-increase-equitable-access-to-eye-health-care/2481482/daily0.7https://crstodayeurope.com/news/nicox-announces-presentations-of-additional-ncx-470-data-at-the-upcoming-world-glaucoma-congress/2481481/daily0.7https://crstodayeurope.com/news/novabay-pharmaceuticals-launches-avenova-eye-health-support-to-comfort-dry-eyes-and-promote-eye-health/2481480/daily0.7https://crstodayeurope.com/news/graybug-announces-name-and-trading-symbol-change/2481478/daily0.7https://crstodayeurope.com/news/kuria-therapeutics-completes-fda-pre-ind-consultation-for-topical-nrf2-activator-for-corneal-endothelial-disease/2481475/daily0.7https://crstodayeurope.com/news/hcp-cureblindness-acquires-sightlife-international/2481471/daily0.7https://crstodayeurope.com/news/researchers-discover-therapeutic-target-to-aid-in-glaucoma-treatment/2481470/daily0.7https://crstodayeurope.com/news/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations/2481468/daily0.7https://crstodayeurope.com/news/new-analysis-of-mri-findings-show-uplizna-reduced-the-formation-of-asymptomatic-optic-nerve-lesions-in-people-with-nmosd/2481467/daily0.7https://crstodayeurope.com/news/istar-medical-initiates-international-star-vi-trial-for-the-use-of-miniject-in-conjunction-with-cataract-surgery/2481466/daily0.7https://crstodayeurope.com/news/harrow-announces-transitional-pass-through-reimbursement-status-for-iheezo/2481462/daily0.7https://crstodayeurope.com/news/ophtec-celebrates-40-year-anniversary-with-new-brand-identity/2481460/daily0.7https://crstodayeurope.com/news/oertli-launches-os-4-surgical-platform/2481459/daily0.7https://crstodayeurope.com/news/kiora-pharmaceuticals-announces-the-acceptance-of-three-abstracts-at-the-2023-arvo-annual-meeting/2481458/daily0.7https://crstodayeurope.com/news/horizon-shares-new-findings-from-survey-of-people-living-with-nmosd/2483699/daily0.7https://crstodayeurope.com/news/sight-sciences-launches-the-ergo-series-of-the-omni-surgical-system/2481457/daily0.7https://crstodayeurope.com/news/tearrestore-announces-positive-clinical-trial-results-for-patients-with-dry-eye-disease/2481456/daily0.7https://crstodayeurope.com/news/new-insights-eye-damage-in-alzheimers-disease-patients/2481455/daily0.7https://crstodayeurope.com/news/eye-love-rock-n-roll-event-headlining-holland-foundation-fundraiser-at-ascrs/2481454/daily0.7https://crstodayeurope.com/news/pioneers-in-retinal-gene-therapies-awarded-international-harrington-prize/2481453/daily0.7https://crstodayeurope.com/news/nih-eye-experts-weigh-in-on-artificial-tears-in-midst-of-infectious-outbreak/2481452/daily0.7https://crstodayeurope.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/daily0.7https://crstodayeurope.com/news/harrow-announces-appointment-of-mark-mannebach-phd-rph-as-head-of-regulatory-affairs-and-pharmacovigilance/2481449/daily0.7https://crstodayeurope.com/news/grifols-enters-into-global-collaboration-and-licensing-agreement-with-selagine-to-develop-immunoglobulin-eye-drops-to-treat-dry-eye-disease/2481446/daily0.7https://crstodayeurope.com/news/akorn-pharma-to-close-all-us-sites/2481445/daily0.7https://crstodayeurope.com/news/oculis-announces-us-public-listing-on-nasdaq/2481444/daily0.7https://crstodayeurope.com/news/vialase-announces-positive-results-of-first-in-human-study-of-femtosecond-laser-image-guided-high-precision-trabeculotomy/2481443/daily0.7https://crstodayeurope.com/news/iridex-introduces-new-research-and-showcases-five-events-at-the-ags-meeting/2481441/daily0.7https://crstodayeurope.com/news/jj-vision-receives-ce-mark-approval-for-the-elita-femtosecond-laser-system/2481440/daily0.7https://crstodayeurope.com/news/new-data-suggest-uplinza-for-the-treatment-of-nmosd-did-not-increase-the-risk-of-covid-19-or-reduce-antibody-levels-from-childhood-vaccines/2481438/daily0.7https://crstodayeurope.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-12-month-safety-clinical-trial-of-reproxalap-in-patients-with-dry-eye-disease/2481437/daily0.7https://crstodayeurope.com/news/ace-vision-group-appoints-cristos-ifantides-md-as-director-clinical-applications-development/2481436/daily0.7https://crstodayeurope.com/news/glaukos-submits-nda-to-fda-for-idose-tr/2481434/daily0.7https://crstodayeurope.com/news/skye-bioscience-receives-positive-safety-review-of-sbi-100-ophthalmic-emulsion-after-second-cohort-of-phase-1-study/2481432/daily0.7https://crstodayeurope.com/news/study-low-brain-pressure-could-be-a-risk-factor-for-developing-glaucoma/2481431/daily0.7https://crstodayeurope.com/news/cdc-expands-recall-of-otc-artificial-tears/2481430/daily0.7https://crstodayeurope.com/news/notal-vision-clinical-trials-demonstrate-value-of-home-oct/2481429/daily0.7https://crstodayeurope.com/news/eyecheq-adds-jai-g-parekh-md-mba-to-its-executive-team/2481428/daily0.7https://crstodayeurope.com/news/spectrum-ophthalmics-launches-new-range-of-dry-eye-products/2481427/daily0.7https://crstodayeurope.com/news/envision-university-sets-agenda-for-in-person-spring-2023-conference/2481426/daily0.7https://crstodayeurope.com/news/belkin-visions-new-glaucoma-laser-technology-now-available-in-germany/2481425/daily0.7https://crstodayeurope.com/news/fda-accepts-orasis-pharmaceuticals-nda-for-csf-1-for-the-treatment-of-presbyopia/2481424/daily0.7https://crstodayeurope.com/news/alcon-launches-experience-academy-app-expanding-remote-on-demand-learning/2481422/daily0.7https://crstodayeurope.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/daily0.7https://crstodayeurope.com/news/celanese-announces-a-research-agreement-with-johns-hopkins-university-to-advance-sustained-ocular-drug-delivery-to-the-suprachoroidal-space/2481417/daily0.7https://crstodayeurope.com/news/aura-biosciences-announces-positive-interim-phase-2-data-of-belzupacap-sarotalocan-for-treatment-of-early-stage-choroidal-melanoma/2481414/daily0.7https://crstodayeurope.com/news/eyenovia-announces-development-collaboration-with-formosa-pharmaceuticals/2481412/daily0.7https://crstodayeurope.com/news/brent-saunders-returns-to-bausch-lomb-to-serve-as-ceo-and-chair-of-the-board-of-directors/2481411/daily0.7https://crstodayeurope.com/news/harrow-launches-next-generation-compounded-atropine-formulations/2481410/daily0.7https://crstodayeurope.com/news/visionix-launches-optovue-solix-fullrange-oct/2481409/daily0.7https://crstodayeurope.com/news/myopia-profile-launches-online-course-to-support-adoption-of-myopia-management-glasses/2481408/daily0.7https://crstodayeurope.com/news/bruder-healthcare-now-exclusive-licensor-of-the-dry-eye-drink/2481407/daily0.7https://crstodayeurope.com/news/fda-accepts-ocuphires-new-drug-application-for-nyxol-eye-drops-for-reversal-of-mydriasis/2481404/daily0.7https://crstodayeurope.com/news/researchers-identify-potential-cause-of-keratoconus/2481402/daily0.7https://crstodayeurope.com/news/radiance-therapeutics-to-present-at-glaucoma-360-new-horizons-forum/2481398/daily0.7https://crstodayeurope.com/news/novaliq-plans-to-file-a-markting-authorization-application-for-cyclasol-in-the-eu-for-the-treatment-of-dry-eye-disease-in-july-2023/2481396/daily0.7https://crstodayeurope.com/news/rxsight-announces-pricing-of-public-offering-of-common-stock/2481395/daily0.7https://crstodayeurope.com/news/kiora-receives-fda-approval-to-start-phase-2-study-of-kio-101/2483698/daily0.7https://crstodayeurope.com/news/fda-accepts-nda-for-aldeyras-reproxalap-for-the-treatment-of-dry-eye-disease/2481392/daily0.7https://crstodayeurope.com/news/omeros-receives-200-million-milestone-payment-from-rayner/2481391/daily0.7https://crstodayeurope.com/news/nidek-launches-cube-a-ophthalmic-surgical-system/2481390/daily0.7https://crstodayeurope.com/news/orbis-announces-3-year-partnership-with-hoya-vision-care/2481389/daily0.7https://crstodayeurope.com/news/viridian-appoints-scott-myers-as-president-and-chief-executive-officer/2481388/daily0.7https://crstodayeurope.com/news/clearside-biomedical-announces-leadership-changes/2481386/daily0.7https://crstodayeurope.com/news/spyglass-pharma-unveils-6-month-data-from-the-first-in-human-trial-of-its-drug-delivery-platform-for-chronic-eye-conditions/2481385/daily0.7https://crstodayeurope.com/news/tracey-technologies-launches-itrace-prime-upgraded-software-for-itrace-aberrometer/2481384/daily0.7https://crstodayeurope.com/news/cdc-provides-update-on-pseudomonas-aeruginosa-associated-with-artificial-tears/2481382/daily0.7https://crstodayeurope.com/news/nidek-and-hoya-vision-care-enter-global-partnership/2481381/daily0.7https://crstodayeurope.com/news/roche-names-teresa-graham-head-of-its-pharma-business/2481379/daily0.7https://crstodayeurope.com/news/harrow-announces-permanent-product-specific-j-code-j2403-for-iheezo-for-ocular-surface-anesthesia/2481378/daily0.7https://crstodayeurope.com/news/eyenuk-secures-the-first-european-union-mdr-certification-for-autonomous-ai-detection-of-diabetic-retinopathy-amd-and-glaucoma/2481377/daily0.7https://crstodayeurope.com/news/nidek-launches-the-al-scan-m-optical-biometer/2481376/daily0.7https://crstodayeurope.com/news/visionary-optics-new-scleral-lens-design-europa-tangent/2481375/daily0.7https://crstodayeurope.com/news/bausch-lomb-and-modulight-announce-fda-approval-of-ml6710i-photodynamic-laser-for-use-with-bausch-lombs-visudyne/2481374/daily0.7https://crstodayeurope.com/news/over-60-countries-and-150-eye-health-organizations-call-on-un-to-create-a-special-envoy-on-vision/2481372/daily0.7https://crstodayeurope.com/news/research-challenges-sugar-hypothesis-of-diabetic-cataract-development/2481371/daily0.7https://crstodayeurope.com/news/kathleen-steele-named-president-of-vsp-ventures/2481370/daily0.7https://crstodayeurope.com/news/glaucoma-research-foundation-to-recognize-santen-pharmaceutical-at-annual-gala-in-san-francisco/2481369/daily0.7https://crstodayeurope.com/news/dr-reddys-launches-generic-version-of-durezol-in-the-us/2481368/daily0.7https://crstodayeurope.com/news/johns-hopkins-researchers-explore-why-episodes-of-low-blood-sugar-worsen-eye-disease-in-people-with-diabetes/2481367/daily0.7https://crstodayeurope.com/news/sight-sciences-announces-1000th-tearcare-customer-installation/2481366/daily0.7https://crstodayeurope.com/news/corcoran-consulting-group-and-conclusn-announce-partnership-aimed-at-improving-ophthalmology-practice-management/2483697/daily0.7https://crstodayeurope.com/news/amazon-launches-5-a-month-subscription-service-for-generic-drugs/2481364/daily0.7https://crstodayeurope.com/news/tfs-healthscience-acquires-appletree-ci-group-expanding-into-ophthalmology/2481363/daily0.7https://crstodayeurope.com/news/cdc-recommends-the-discontinued-ezricare-artificial-tears/2483696/daily0.7https://crstodayeurope.com/news/harrow-closes-acquisition-of-us-rights-to-ilevro-nevanac-vigamox-maxidex-and-triesence-and-will-begin-receiving-net-profit-payments-for-acquired-products/2481361/daily0.7https://crstodayeurope.com/news/outlook-therapeutics-appoints-surendra-sharma-md-and-glen-olsheim-to-leadership-positions/2481359/daily0.7https://crstodayeurope.com/news/trefoil-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-tthx1114-for-treatment-of-corneal-epithelial-defects/2481356/daily0.7https://crstodayeurope.com/news/cxl-ophthalmics-appoints-jonathan-talamo-md-as-chair-of-the-board/2481355/daily0.7https://crstodayeurope.com/news/topcon-achieves-iso-27001-certification-of-its-harmony-rs-clinical-data-management-system/2481354/daily0.7https://crstodayeurope.com/news/bausch-lomb-acquires-acufocus/2481353/daily0.7https://crstodayeurope.com/news/study-zebrafish-model-helps-explain-eye-development/2481352/daily0.7https://crstodayeurope.com/news/core-names-its-top-10-of-2022-scientific-papers/2481351/daily0.7https://crstodayeurope.com/news/eyenovia-positive-evidence-that-optejet-delivery-technology-decreased-inflammation-from-preserved-glaucoma-solutions-compared-to-drops/2481349/daily0.7https://crstodayeurope.com/news/visus-therapeutics-appoints-eric-d-donnenfeld-md-to-board-of-directors/2481347/daily0.7https://crstodayeurope.com/news/glaukos-announces-positive-results-for-idose-tr-exchange-trial-highlighting-favorable-safety-and-tolerability/2481346/daily0.7https://crstodayeurope.com/news/keranova-announces-clinical-study-results-for-robotic-laser-technology/2481345/daily0.7https://crstodayeurope.com/news/staar-surgical-announces-partnership-with-actress-peyton-list/2481344/daily0.7https://crstodayeurope.com/news/glaukos-announces-positive-clinical-updates-for-several-corneal-health-pipeline-programs/2481343/daily0.7https://crstodayeurope.com/news/rayner-launches-peer2peer-the-podcast-for-clinical-education/2481342/daily0.7https://crstodayeurope.com/news/neurotech-pharmaceuticals-appoints-scott-hunter-as-chief-commercial-officer/2481341/daily0.7https://crstodayeurope.com/news/sifi-announces-license-agreement-with-avanzanite-bioscience-for-acanthamoeba-keratitis-treatment-akantior/2481340/daily0.7https://crstodayeurope.com/news/market-scope-lens-based-procedures-will-push-retail-refractive-surgery-market-to-12-billion/2481338/daily0.7https://crstodayeurope.com/news/alcon-champions-access-to-eye-care-with-opening-of-childrens-vision-center-in-fort-worth-texas/2481337/daily0.7https://crstodayeurope.com/news/fci-ophthalmics-announces-availability-of-ezypor-polyethylene-orbital-implant/2481336/daily0.7https://crstodayeurope.com/news/bausch-lomb-introduces-enhanced-preservision-areds-2-formula-mini-soft-gels-with-ocusorb/2481335/daily0.7https://crstodayeurope.com/news/viridian-announces-positive-data-from-ongoing-phase-12-trial-evaluating-low-dose-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481334/daily0.7https://crstodayeurope.com/news/ocuphire-pharma-announces-first-patient-enrolled-in-vega-2-pivotal-phase-3-trial-of-nyxol-in-presbyopia/2481333/daily0.7https://crstodayeurope.com/news/amber-ophthalmics-announces-positive-topline-phase-2-data-evaluating-nexagon-for-the-treatment-of-persistent-corneal-epithelial-defect-pced/2481332/daily0.7https://crstodayeurope.com/news/alimera-sciences-appoints-industry-veteran-russell-l-skibsted-as-chief-financial-officer/2481331/daily0.7https://crstodayeurope.com/news/bausch-lomb-and-novaliq-announce-publication-of-pivotal-phase-3-data-on-nov03-perfluorohexyloctane-in-ophthalmology/2481330/daily0.7https://crstodayeurope.com/news/acufocus-announces-first-commercial-patients-treated-with-the-ic-8-apthera-iol/2481329/daily0.7https://crstodayeurope.com/news/eyecare-partners-expands-footprint-in-oklahoma-with-retinal-associates-of-oklahoma/2481328/daily0.7https://crstodayeurope.com/news/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1/2481326/daily0.7https://crstodayeurope.com/news/shamir-glacier-plus-metaform-on-transitions-signature-gen-8-brown-and-grey-now-available/2481325/daily0.7https://crstodayeurope.com/news/harrow-announces-availability-of-fortisite-formulations-for-in-office-use/2481322/daily0.7https://crstodayeurope.com/news/mobius-therapeutics-granted-new-us-patent-for-injected-ophthalmic-mitomycin-c/2481319/daily0.7https://crstodayeurope.com/news/elios-vision-announces-registration-of-elios-in-the-united-kingdom/2481318/daily0.7https://crstodayeurope.com/news/visionsprings-screening-methodology-is-adopted-by-the-world-health-organization-to-increase-global-access-to-reading-glasses/2483695/daily0.7https://crstodayeurope.com/news/iveric-bio-announces-the-addition-of-pravin-u-dugel-md-to-its-board-of-directors/2481317/daily0.7https://crstodayeurope.com/news/bausch-lomb-and-glaucoma-research-foundation-announce-launch-of-screen-protect-cure-campaign/2481316/daily0.7https://crstodayeurope.com/news/orasis-pharmaceuticals-submits-nda-for-investigational-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia/2481315/daily0.7https://crstodayeurope.com/news/retina-group-of-new-england-joins-retina-consultants-of-america/2481314/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-announces-fda-acceptance-of-ind-application-for-kpi-012-for-the-treatment-of-pced/2481312/daily0.7https://crstodayeurope.com/news/opus-genetics-acquires-rights-to-two-gene-therapy-product-candidates-for-inherited-retinal-diseases/2481311/daily0.7https://crstodayeurope.com/news/aao-prior-authorization-reform-effort-gets-boost-from-cms/2481310/daily0.7https://crstodayeurope.com/news/melt-pharmaceuticals-melt-300-achieves-primary-sedation-endpoint-in-phase-2-pivotal-efficacy-and-safety-study/2481307/daily0.7https://crstodayeurope.com/news/viridian-therapeutics-announces-first-patient-enrolled-in-the-thrive-phase-3-trial-in-patients-with-thyroid-eye-disease/2483694/daily0.7https://crstodayeurope.com/news/elios-vision-announces-registration-of-elios-in-france/2481304/daily0.7https://crstodayeurope.com/news/new-genetic-mutation-behind-childhood-glaucoma-identified/2481303/daily0.7https://crstodayeurope.com/news/staar-surgical-ceo-caren-mason-to-retire-tom-frinzi-appointed-new-ceo/2481302/daily0.7https://crstodayeurope.com/news/parexel-enters-agreement-with-myeyedr-to-refer-patients-into-existing-and-future-ophthalmology-clinical-trials/2481298/daily0.7https://crstodayeurope.com/news/ai-diagnostics-startup-altris-ai-raises-1-million/2481296/daily0.7https://crstodayeurope.com/news/novasight-introduces-curesight-to-the-us-and-names-a-new-vp-of-sales-marketing/2481295/daily0.7https://crstodayeurope.com/news/thea-pharma-announces-fda-approval-of-glaucoma-drug-iyuzeh/2481294/daily0.7https://crstodayeurope.com/news/harrow-enters-into-agreement-to-acquire-exclusive-us-rights-to-five-ophthalmic-products-from-novartis/2481292/daily0.7https://crstodayeurope.com/news/eversight-and-the-department-of-health-abu-dhabi-partner-to-establish-uaes-first-eye-and-tissue-bank/2481291/daily0.7https://crstodayeurope.com/news/eyenovia-announces-fda-acceptance-of-new-drug-application-for-mydcombi-for-in-office-pupil-dilation/2481289/daily0.7https://crstodayeurope.com/news/amgen-to-buy-horizon-therapeutics-in-deal-worth-278-billion/2481288/daily0.7https://crstodayeurope.com/news/nidek-launches-fully-assisted-refraction-system-for-ts-610/2481287/daily0.7https://crstodayeurope.com/news/azura-ophthalmics-presents-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction/2481286/daily0.7https://crstodayeurope.com/news/visiox-pharma-announces-fda-acceptance-of-nda-for-glaucoma/2481285/daily0.7https://crstodayeurope.com/news/cord-files-for-premarket-approval-with-the-fda-for-the-sc9-iol-for-cataract-surgery/2481284/daily0.7https://crstodayeurope.com/news/eyenovia-announces-promotion-of-bren-kern-to-chief-operating-officer-and-corporate-vice-president/2481283/daily0.7https://crstodayeurope.com/news/conference-and-exhibit-hall-registration-now-open-for-vision-expo-east-2023-taking-place-march-16-19-in-new-york-city/2481282/daily0.7https://crstodayeurope.com/news/lumibird-medical-launches-tango-reflex-neo-yagslt-laser/2481281/daily0.7https://crstodayeurope.com/news/euclid-vision-announces-winners-of-its-first-resident-scholarship-award/2481279/daily0.7https://crstodayeurope.com/news/ocuphire-pharma-submits-new-drug-application-to-fda-for-nyxol-eye-drops-for-reversal-of-mydriasis/2481278/daily0.7https://crstodayeurope.com/news/aoa-survey-doctors-of-optometry-embrace-myopia-management/2481277/daily0.7https://crstodayeurope.com/news/sifi-launches-epicolin-glaucoma-supplement-in-italy/2481276/daily0.7https://crstodayeurope.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care-1/2481275/daily0.7https://crstodayeurope.com/news/improved-pc-iol-technology-is-key-to-recent-and-future-premium-cataract-surgery-growth/2481273/daily0.7https://crstodayeurope.com/news/istar-medical-expands-commercial-rollout-of-miniject-with-first-surgeries-in-sweden-and-norway/2481272/daily0.7https://crstodayeurope.com/news/harrow-and-ior-partners-expand-national-product-supply-agreement/2481267/daily0.7https://crstodayeurope.com/news/re-vana-therapeutics-raises-119-million-to-advance-drug-delivery-products/2481266/daily0.7https://crstodayeurope.com/news/ripple-therapeutics-appoints-jonathan-talamo-md-to-chair-of-the-board/2481265/daily0.7https://crstodayeurope.com/news/lighthouse-guild-and-bionic-sight-announce-partnership-designed-to-expand-treatment-options-for-people-who-are-blind/2481264/daily0.7https://crstodayeurope.com/news/aldeyra-therapeutics-submits-nda-to-the-fda-for-reproxalap-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2481263/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-submits-of-investigational-nda-for-kpi-012-for-the-treatment-of-persistent-corneal-epithelial-defect/2481262/daily0.7https://crstodayeurope.com/news/btig-to-host-ophthalmology-day-on-november-29-2022/2481261/daily0.7https://crstodayeurope.com/news/new-uci-led-study-shows-repeated-stress-accelerates-aging-of-the-eye/2481260/daily0.7https://crstodayeurope.com/news/meivertor-single-handed-upper-and-lower-eyelid-eversion-tool-now-available/2481259/daily0.7https://crstodayeurope.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/daily0.7https://crstodayeurope.com/news/graybug-and-calcimedica-enter-into-definitive-merger-agreement/2481257/daily0.7https://crstodayeurope.com/news/oculis-announces-publication-of-positive-phase-2-data-investigating-topical-anti-tnfa-agent-licaminlimab-ocs-02-in-acute-anterior-uveitis/2481255/daily0.7https://crstodayeurope.com/news/sightpath-medical-acquires-accusite-surgical/2481253/daily0.7https://crstodayeurope.com/news/scientists-say-eye-disease-drug-may-also-help-fight-covid/2483693/daily0.7https://crstodayeurope.com/news/staar-surgical-opens-evo-experience-center-in-united-states/2481249/daily0.7https://crstodayeurope.com/news/azura-ophthalmics-announces-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction/2481247/daily0.7https://crstodayeurope.com/news/bloomberg-novartis-considering-sale-of-ophthalmology-unit/2481246/daily0.7https://crstodayeurope.com/news/dopavision-appoints-dirk-sauer-phd-as-chair-of-the-companys-advisory-board/2483692/daily0.7https://crstodayeurope.com/news/visionary-optics-announces-appointment-of-director-of-clinical-and-scientific-affairs/2483691/daily0.7https://crstodayeurope.com/news/vialase-makes-several-appointments-to-its-executive-team/2481244/daily0.7https://crstodayeurope.com/news/essilorluxottica-supports-new-wspos-independent-medical-education-program-on-myopia-management/2481243/daily0.7https://crstodayeurope.com/news/heru-surpasses-clinical-milestone-of-100000-eyes-examined/2481242/daily0.7https://crstodayeurope.com/news/nidek-launches-the-nt-1p-non-contact-tonopachymeter/2481241/daily0.7https://crstodayeurope.com/news/viridian-announces-positive-data-from-ongoing-phase-12-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481240/daily0.7https://crstodayeurope.com/news/study-vision-impairment-is-associated-with-as-many-as-100000-us-dementia-cases/2481238/daily0.7https://crstodayeurope.com/news/luminopia-announces-oversubscribed-seed-extension-financing-round-to-fund-amblyopia-treatment/2481237/daily0.7https://crstodayeurope.com/news/aura-announces-global-phase-3-trial-design-with-suprachoroidal-route-of-administration-of-belzupacap-sarotalocan-in-early-stage-choroidal-melanoma/2483690/daily0.7https://crstodayeurope.com/news/harrow-launches-atropinecom/2481236/daily0.7https://crstodayeurope.com/news/fda-accepts-tarsus-new-drug-application-for-tp-03-for-treatment-of-demodex-blepharitis/2481235/daily0.7https://crstodayeurope.com/news/mediprint-ophthalmics-announces-it-has-initiated-its-sight-2-phase-2b-clinical-study-for-its-lead-asset/2481231/daily0.7https://crstodayeurope.com/news/prevent-blindness-names-jim-mcgrann-chair-of-its-board-of-directors-adds-dr-susan-a-primo-mph-faao-and-susan-l-stone-mba-as-new-members/2483689/daily0.7https://crstodayeurope.com/news/viatris-acquires-oyster-point-pharma/2481230/daily0.7https://crstodayeurope.com/news/nicox-outlines-future-development-and-partnering-plans-for-ncx-470-in-glaucoma/2481228/daily0.7https://crstodayeurope.com/news/the-vision-council-releases-focused-insights-2022-digital-habits/2481225/daily0.7https://crstodayeurope.com/news/medicontur-launches-bi-flex-elon-nondiffractive-edof-iol/2481224/daily0.7https://crstodayeurope.com/news/market-scope-safer-and-more-effective-glaucoma-surgical-options-expected-to-double-global-revenue-by-2027/2481223/daily0.7https://crstodayeurope.com/news/sight-sciences-announces-publication-of-clinical-data-demonstrating-standalone-effectiveness-of-the-omni-surgical-system-in-pseudophakic-glaucoma-patients-with-uncontrolled-pressure-following-a-previous-combination-cataract-stent-procedure/2481221/daily0.7https://crstodayeurope.com/news/aramis-biosciences-completes-enrollment-of-its-phase-2-clinical-trial-evaluating-a197-for-the-treatment-of-dry-eye-disease/2481219/daily0.7https://crstodayeurope.com/news/in-final-rule-cms-rejects-proposal-to-make-facility-payments-for-office-based-ophthalmic-surgeries/2481218/daily0.7https://crstodayeurope.com/news/world-sight-day-photo-competition-winners/2483688/daily0.7https://crstodayeurope.com/news/replay-launches-its-first-hsv-gene-therapy-company-eudora-focused-on-retinal-eye-disease/2481216/daily0.7https://crstodayeurope.com/news/ocuphire-announces-peer-reviewed-publication-for-nyxol-and-strategic-partnership-with-asoa/2481215/daily0.7https://crstodayeurope.com/news/topcon-offers-maestro2-oct-certification-course/2481213/daily0.7https://crstodayeurope.com/news/biotissue-completes-name-change/2481211/daily0.7https://crstodayeurope.com/news/heru-makes-appointments-to-its-executive-leadership-team/2481210/daily0.7https://crstodayeurope.com/news/nicox-reports-achieving-primary-objective-in-mont-blanc-the-first-phase-3-glaucoma-trial-for-ncx-470/2481209/daily0.7https://crstodayeurope.com/news/helen-keller-intl-and-partners-celebrate-vision-milestone-screening-1-million-students-in-new-york-city/2481208/daily0.7https://crstodayeurope.com/news/vyluma-announces-positive-results-from-phase-3-champ-study-of-nvk002-for-treatment-of-myopia-progression-in-children/2481205/daily0.7https://crstodayeurope.com/news/eyemed-vision-care-names-matt-macdonald-president/2481204/daily0.7https://crstodayeurope.com/news/aurion-biotech-wins-prix-galien-startup-award/2481203/daily0.7https://crstodayeurope.com/news/altris-launches-new-artificial-intelligence-platform-for-automated-oct-scans/2481202/daily0.7https://crstodayeurope.com/news/lumata-health-raises-4-million-in-series-a-funding-to-scale-its-human-led-intelligent-eye-care-management-platform/2481201/daily0.7https://crstodayeurope.com/news/amydis-awarded-third-grant-from-the-michael-j-fox-foundation-to-support-first-in-human-study-of-a-retinal-tracer-for-parkinsons-disease/2481198/daily0.7https://crstodayeurope.com/news/radiance-therapeutics-co-founders-wendell-lutz-phd-honored-by-the-american-society-of-radiation-oncology-astro/2481194/daily0.7https://crstodayeurope.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care/2481193/daily0.7https://crstodayeurope.com/news/dorc-acquires-peregrine-surgical-and-completes-acquisition-of-the-remaining-stake-in-wefis/2481192/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2481191/daily0.7https://crstodayeurope.com/news/tarsus-to-present-additional-saturn-2-pivotal-phase-3-trial-data-at-the-american-academy-of-optometry-2022-annual-meeting/2481189/daily0.7https://crstodayeurope.com/news/ocuphire-announces-six-poster-presentations-on-nyxol-and-apx3330-at-the-american-academy-of-optometry-annual-meeting/2481187/daily0.7https://crstodayeurope.com/news/novaliq-announces-fda-acceptance-of-the-new-drug-application-for-cyclasol-for-the-treatment-of-dry-eye-disease/2481186/daily0.7https://crstodayeurope.com/news/lori-tierney-joins-johnson-johnson-vision-as-president-of-americas/2481184/daily0.7https://crstodayeurope.com/news/eyenuk-secures-26-million-series-a-funding-to-accelerate-global-access-to-ai-powered-eye-screening-technology/2481183/daily0.7https://crstodayeurope.com/news/azura-ophthalmics-expands-broad-intellectual-property-portfolio-to-12-us-and-european-patents/2481182/daily0.7https://crstodayeurope.com/news/brian-boxer-wachler-md-announces-new-book-published-by-rowman-littlefieldpenguin-random-house/2483687/daily0.7https://crstodayeurope.com/news/nicox-provides-third-quarter-2022-financial-and-business-highlights/2481179/daily0.7https://crstodayeurope.com/news/salvat-laboratories-announces-submission-of-new-drug-application-to-the-fda-for-clobetasol-nanoemulsion-for-treating-inflammation-and-pain-after-ocular-surgery/2483686/daily0.7https://crstodayeurope.com/news/olleyes-announces-partnership-with-tobii-to-incorporate-advanced-eye-tracking-features-into-visuall-ets-model/2481178/daily0.7https://crstodayeurope.com/news/oculis-sa-and-european-biotech-acquisition-corp-announce-agreement-to-create-nasdaq-listed-biopharmaceutical-company/2481177/daily0.7https://crstodayeurope.com/news/lenstec-rebrands-its-newly-approved-multifocal-iol-to-clearview-3/2481174/daily0.7https://crstodayeurope.com/news/uci-team-demonstrates-the-adult-brain-has-the-potential-to-partially-recover-from-inherited-blindness/2481173/daily0.7https://crstodayeurope.com/news/survey-identifies-diabetic-retinopathy-screening-and-care-as-top-outreach-eye-care-need-in-utah/2481172/daily0.7https://crstodayeurope.com/news/eyecare-partners-expands-footprint-in-northern-ohio-with-three-additional-practices/2481171/daily0.7https://crstodayeurope.com/news/cellusion-and-minaris-regenerative-medicine-enter-alliance-for-the-manufacturing-of-corneal-endothelial-cell-regenerative-therapy/2481170/daily0.7https://crstodayeurope.com/news/new-campaign-calls-for-eye-health-to-be-equal-this-world-sight-day/2481169/daily0.7https://crstodayeurope.com/news/tarsus-announces-transition-plans-for-board-of-directors/2481168/daily0.7https://crstodayeurope.com/news/patientpoint-acquires-rendia-to-accelerate-expansion-into-ophthalmology-specialty/2481166/daily0.7https://crstodayeurope.com/news/tearclear-announces-positive-topline-results-from-clear-phase-3-study-for-the-treatment-of-glaucoma-with-tc-002-latanoprost-ophthalmic-solution-0005/2481165/daily0.7https://crstodayeurope.com/news/harrow-sells-non-ophthalmic-compounding-business/2481162/daily0.7https://crstodayeurope.com/news/moria-expands-its-footprint-into-eye-surgery-by-acquiring-alchimia-srl/2481161/daily0.7https://crstodayeurope.com/news/santen-announces-health-canada-approval-for-cationorm-plus-to-relieve-the-symptoms-of-dry-eye-and-ocular-allergy/2481160/daily0.7https://crstodayeurope.com/news/study-finds-eyenuk-artificial-intelligence-detects-diabetic-retinopathy-with-greater-sensitivity-than-dilated-exams/2481158/daily0.7https://crstodayeurope.com/news/santen-filing-accepted-by-ema-for-review-of-application-for-stn1013001-cationic-emulsion-of-latanoprost-50mgml-in-glaucoma/2481157/daily0.7https://crstodayeurope.com/news/haag-streit-announces-the-winners-of-the-slit-lamp-imaging-competition-2022/2481154/daily0.7https://crstodayeurope.com/news/first-dry-eye-disease-education-initiative-event-from-world-council-of-optometry-and-alcon-set-for-november-8/2481153/daily0.7https://crstodayeurope.com/news/clearside-positive-data-presentations-at-aao-annual-meeting-demonstrate-utility-and-versatility-of-clearside-biomedicals-proprietary-suprachoroidal-space-platform/2481151/daily0.7https://crstodayeurope.com/news/cellusion-and-minaris-regenerative-medicine-enter-into-business-alliance-for-the-manufacturing-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy/2481150/daily0.7https://crstodayeurope.com/news/schwind-eye-tech-solutions-announces-management-changes/2481149/daily0.7https://crstodayeurope.com/news/novasight-announces-fda-510k-clearance-of-curesight-digital-therapy-for-amblyopia/2481148/daily0.7https://crstodayeurope.com/news/aura-biosciences-announces-interim-phase-2-data-evaluating-suprachoroidal-belzupacap-sarotalocan-for-the-treatment-of-patients-with-early-stage-choroidal-melanoma/2483685/daily0.7https://crstodayeurope.com/news/shore-capital-partners-announces-sale-of-eyesouth-partners/2481146/daily0.7https://crstodayeurope.com/news/study-specialized-smart-soft-contact-lenses-can-address-global-issue-of-glaucoma-diagnosis-management/2481144/daily0.7https://crstodayeurope.com/news/new-study-shows-people-with-glaucoma-are-at-significant-risk-of-alzheimers-disease/2481142/daily0.7https://crstodayeurope.com/news/aao-latest-research-from-the-worlds-largest-eye-disease-data-registry/2481141/daily0.7https://crstodayeurope.com/news/spyglass-pharma-presents-3-month-data-from-the-first-in-human-trial-of-its-drug-delivery-platform-for-chronic-eye-conditions/2481140/daily0.7https://crstodayeurope.com/news/haag-streit-to-host-a-series-of-educational-webinars-as-part-of-its-biometry-focus-month-in-november/2481139/daily0.7https://crstodayeurope.com/news/myze-eye-health-focused-digital-platform-launched/2481138/daily0.7https://crstodayeurope.com/news/trefoil-therapeutics-announces-positive-phase-2-study-data-showing-corneal-regeneration-and-vision-recovery-following-descemet-stripping-only-dso-surgery/2481137/daily0.7https://crstodayeurope.com/news/glaukos-technologies-featured-in-numerous-scientific-abstracts-at-the-2022-american-academy-of-ophthalmology-annual-meeting/2481136/daily0.7https://crstodayeurope.com/news/cofi-launches-integration-with-alphaeon-credit-to-bring-multi-party-financing-to-ophthalmology-practices/2483684/daily0.7https://crstodayeurope.com/news/imprimisrx-launches-fortisite-tobramycin-15-vancomycin-5-compounded-antibiotic-formulation/2481135/daily0.7https://crstodayeurope.com/news/alcon-completes-availability-of-clareon-portfolio-with-clareon-toric-during-aao-2022/2481134/daily0.7https://crstodayeurope.com/news/tarsus-launches-look-at-the-lids-campaign-to-encourage-eye-care-professionals-to-identify-and-diagnose-demodex-blepharitis/2481133/daily0.7https://crstodayeurope.com/news/ocuphire-expands-medical-advisory-board-with-seven-new-kols-expands-leadership-team/2481132/daily0.7https://crstodayeurope.com/news/iridex-to-showcase-its-non-incisional-treatments-for-glaucoma-and-introduce-sweep-management-software-at-aao-2022/2481130/daily0.7https://crstodayeurope.com/news/tearsolutions-announces-results-from-first-in-human-clinical-trial-published-in-cornea/2481129/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-introduces-tecnis-symfony-optiblue-edof-iol-the-latest-pc-iol-powered-by-intelilight-technology/2481128/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-expands-access-to-myopia-management-for-more-patients-with-abiliti-overnight-lenses/2481127/daily0.7https://crstodayeurope.com/news/ora-launches-the-ora-eyecup-an-ophthalmic-research-technology-at-eyecelerator-2022/2483683/daily0.7https://crstodayeurope.com/news/neurophth-announces-first-patient-dosed-in-phase-3-clinical-trial-for-the-gene-therapy-treatment-of-lhon/2481126/daily0.7https://crstodayeurope.com/news/sight-sciences-to-feature-interactive-panel-discussions-of-real-world-use-of-the-omni-surgical-system-as-a-standalone-glaucoma-treatment-at-aao/2481125/daily0.7https://crstodayeurope.com/news/visus-therapeutics-acquires-assets-of-viewpoint-therapeutics/2481124/daily0.7https://crstodayeurope.com/news/tarsus-to-present-saturn-2-pivotal-phase-3-trial-data-and-saturn-1-extension-study-long-term-safety-data-at-upcoming-eye-care-meetings/2481123/daily0.7https://crstodayeurope.com/news/harrow-announces-fda-approval-of-iheezo-for-ocular-surface-anesthesia/2481122/daily0.7https://crstodayeurope.com/news/bausch-lomb-will-present-scientific-data-and-analyses-during-world-cornea-congress/2481119/daily0.7https://crstodayeurope.com/news/eyecare-partners-launches-new-innovation-center/2481118/daily0.7